Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
1.300
+0.070 (+5.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
August 18, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
June 30, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Business Advisory Board
June 05, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
May 24, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at BIO International Convention 2023
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with First Quarter 2023 Financial Results
May 05, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
April 28, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
April 27, 2023
U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 20, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
April 14, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis
From
Ocugen
Via
GlobeNewswire
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
March 31, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
March 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
March 07, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
March 06, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
February 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.